Liberalization of Visiting Policies in ICU for Reducing High Risk of Post-traumatic Stress Disorder
NCT ID: NCT03846323
Last Updated: 2019-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
1289 participants
INTERVENTIONAL
2009-04-18
2018-02-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participating ICUs had restrictive visiting policies (i.e., \<6 hours/day) before randomization.
After an observational period and a washout period, participating ICUs were randomized either to maintain their visiting policies or to liberalize their visiting policies (24 hours a day, 7 days a week.)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Covid-19 Restrictive Measure on Anxiety, Depression and PTSD for Relatives of ICU Patients
NCT04430049
Reducing Post-traumatic Stress Disorder After ICU Discharge With the IPREA3 Program
NCT03991611
Experience of Staying in Intensive Care and Impact on Quality of Life
NCT07339891
Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
NCT03278171
Improving FAMily Members' Experience in the ICU
NCT05461521
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is currently unknown what type of interventions/ strategies to cope with postintensive care syndrome family would produce the best improvement. Experts suggest that symptoms in family members are potentially amenable to intervention by ICU staff. One intervention to reduce PTSD could be a liberalization of the visiting hours. However, restrictions on visiting hours in the intensive care unit (ICU) are usually adopted worldwide.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Visiting policies: open 24h/24
Visiting policies: 24 hours a day, 7 days a week
Visiting policies: 24 hours a day, 7 days a week
Restriction of visiting policies
Restriction of visiting policies \< 6 hours
Restriction of visiting policies < 6 hours
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Visiting policies: 24 hours a day, 7 days a week
Restriction of visiting policies < 6 hours
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* mechanical ventilation expected for more than 48 h and inclusion between day 3 and 5 from the beginning of mechanical ventilation,
* patient having a family member speaking and understanding French, and with the ability to visit his/her relative during the ICU stay,
* patient and his/her relative consenting to participate in the study, or obtention of family consent in case of patient incompetency
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
LILA BOUADMA
Role: PRINCIPAL_INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AOM08226
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.